Interferon beta-1b (Betaferon, BAY86-5046)

DRUG3 trials

Sponsors

Bayer

Conditions

Multiple Sclerosis

Unknown Phase

Depression and Fatigue in MS Patients Treated With Betaferon.

CompletedNCT01354665

BayerMultiple Sclerosis

Start: 2010-05-31End: 2013-06-30Updated: 2015-01-21

Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon

CompletedNCT02486640

BayerMultiple Sclerosis

Start: 2015-09-08End: 2020-01-16Updated: 2023-07-24

Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study

CompletedNCT03134573

BayerMultiple Sclerosis

Start: 2017-09-15End: 2018-05-09Updated: 2019-03-26

Related Papers

Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT® Autoinjector: A Prospective Observational Cohort Study

Frontiers in Neurology2021-02-246 citations

Assessment of Medication Adherence Using a Medical App Among Patients With Multiple Sclerosis Treated With Interferon Beta-1b: Pilot Digital Observational Study (PROmyBETAapp)

Journal of Medical Internet Research2019-07-2912 citations

Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.

2017-09-0613 citations